https://assets.capyfin.com/instruments/678fdc13234e27009c5d5779.png avatar
Neogen
🇺🇸 NASDAQ:NEOG
View Company
OverviewEarningsDividends
•
Nov 30, 2024

Neogen Q2 2025 Earnings Report

Neogen's second quarter reflected steady progress with improvement across the business, core revenue growth accelerating in both segments, sequential margin expansion, and significantly better free cash flow.

Key Takeaways

Neogen Corporation announced preliminary results for Q2 2025, with revenue of $231.3 million. The company reported a net loss of $456.3 million due to a non-cash goodwill impairment, but adjusted net income was $24.4 million, or $0.11 per diluted share. The company is updating its full-year outlook.

Revenue reached $231.3 million, a 0.7% increase compared to the previous year.

Net loss was $456.3 million, or $(2.10) per diluted share, due to a non-cash goodwill impairment charge.

Adjusted Net Income was $24.4 million, or $0.11 per diluted share.

Adjusted EBITDA was $51.4 million.

Total Revenue
$231M
Previous year: $230M
+0.7%
EPS
$0.11
Previous year: $0.11
+0.0%
Adjusted EBITDA Margin
22.2%
Previous year: 24%
-7.5%
Gross Profit
$113M
Previous year: $117M
-2.9%
Cash and Equivalents
$140M
Previous year: $206M
-31.8%
Free Cash Flow
$23.1M
Previous year: -$8.7M
-365.4%
Total Assets
$4.05B
Previous year: $4.6B
-11.9%

Neogen

Neogen

Neogen Revenue by Segment

Forward Guidance

The company is updating its full-year outlook. Revenue is now expected to be in the range of $905 million to $925 million. Adjusted EBITDA is now expected to be in the range of $205 million to $215 million.

Challenges Ahead

  • Strengthening of the U.S. dollar.
  • A delay in the ramp-up of sample collection production.
  • The voluntary attrition of genomics revenue related to restructuring activities.
  • Lower revenue.
  • Higher shipping and distribution costs.

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View Neogen